Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.

被引：0

作者：

Ahn, Myung-Ju

Kim, HyeRyun

Yang, James Chih-Hsin

Han, Ji-Youn

Lee, Jong Seok

Hochmair, Maximilian J.

Li, Jacky Yu-Chung

Chang, Gee-Chen

Lee, Ki Hyeong

Gridelli, Cesare

Campelo, Rosario Garcia

Delmonte, Angelo

Kim, Dong-Wan

Kerstein, David

Ni, Quanhong

Zhang, Pingkuan

Popat, Sanjay

Camidge, D. Ross

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[2] Yonsei Univ, Severance Hosp, Seoul, South Korea

[3] Natl Taiwan Univ, Taipei, Taiwan

[4] Natl Canc Ctr, Ctr Lung Canc, Goyang, Gyeonggi Do, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[6] Dept Resp & Crit Care Med, Vienna, Austria

[7] Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria

[8] Hong Kong United Oncol Ctr, Kowloon, Hong Kong, Peoples R China

[9] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan

[10] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan

[11] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[12] AOSG Moscati, Avellino, Italy

[13] Complejo Hosp Univ A Coruna, Coruna, Spain

[14] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[15] Seoul Natl Univ Hosp, Seoul, South Korea

[16] Millennium Pharmaceut Inc, Cambridge, MA USA

[17] Royal Marsden Hosp, London, England

[18] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9026

引用

页数：2

共 50 条

[21] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
Kim, Dong-Wan
Tiseo, Marcello
Ahn, Myung-Ju
Reckam, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Lange, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William G.
Kerstein, David
Haluska, Frank G.
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial
Ahn, Myung-Ju
Camidge, D. Ross
Tiseo, Marcello
Reckamp, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Langer, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William
Kerstein, David
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Popat, S.
Liu, G.
Lu, S.
Song, G.
Samnotra, V.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2019, 30
[24] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Camidge, R.
Kim, H. R.
Ahn, M.
Yang, J. C.
Han, J.
Lee, J.
Hochmair, M.
Li, J. Y.
Chang, G.
Lee, K.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
[25] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials
Huber, R.
Gettinger, S.
Kim, D. -W
Bazhenova, L.
Hansen, K.
Tiseo, M.
Langer, C.
Paz-Ares Rodriguez, L.
West, H.
Reckamp, K.
Weiss, G.
Smit, E.
Hochmair, M.
Kim, S. -W
Ahn, M. -J
Kim, E.
Groen, H.
Pye, J.
Vranceanu, F.
Camidge, D. R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 4 - 5
[26] Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
Tiseo, M.
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A. I.
Gettinger, S. N.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, R.
ANNALS OF ONCOLOGY, 2022, 33 : S44 - S45
[27] Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial
Campelo, M. R. Garcia
Wan, Y.
Lin, H. M.
Chen, T.
Shen, J.
Zhang, P.
Camidge, D. R.
LUNG CANCER, 2023, 185
[28] Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
Gettinger, Scott N.
Huber, Rudolf M.
Kim, Dong-Wan
Bazhenova, Lyudmila
Hansen, Karin Holmskov
Tiseo, Marcello
Langer, Corey J.
Paz-Ares, Luis G.
West, Howard
Reckamp, Karen L.
Weiss, Glen J.
Smit, Egbert F.
Hochmair, Maximilian
Kim, Sang-We
Ahn, Myung-Ju
Kim, Edward S.
Groen, Harry J. M.
Pye, Joanna
Vranceanu, Florin
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK plus Non-Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
Kim, D.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K. Holmskov
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares Rodriguez, L.
Smit, E.
Reichmann, W.
Kerstein, D.
Haluska, F.
Camidge, D.
ANNALS OF ONCOLOGY, 2016, 27
[30] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
Bazhenova, Lyudmila
Gettinger, Scott N.
Langer, Corey J.
Salgia, Ravi
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice Tsang
Weiss, Glen J.
Haney, Jeff
Rivera, Victor M.
Kerstein, David
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →